Compare RKDA & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | HCWB |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.5M |
| IPO Year | 2015 | 2021 |
| Metric | RKDA | HCWB |
|---|---|---|
| Price | $3.74 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 12.7K | ★ 151.3K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,173,000.00 | $422,026.00 |
| Revenue This Year | $21.31 | $178.64 |
| Revenue Next Year | $28.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.31 | N/A |
| 52 Week Low | $2.53 | $1.52 |
| 52 Week High | $6.71 | $41.20 |
| Indicator | RKDA | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 31.34 |
| Support Level | $3.58 | $1.52 |
| Resistance Level | $3.87 | $2.15 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 66.36 | 37.51 |
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.